Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study.

Research output: Contribution to journalArticle

Bibtex

@article{de19f34081fa4b30a222fa25e9c1f40d,
title = "Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study.",
abstract = "Chronic migraine (CM) is a type of chronic daily headache. CM presents a challenge to primary care physicians and neurologists. Any new treatment showing efficiency would therefore be of great importance. Atenolol together with other beta-blockers is a first-line choice in episodic migraine prophylaxis. Clinical findings support the efficacy of atenolol in doses of 50 to 200 mg/day.",
author = "Bengt Edvardsson",
year = "2013",
doi = "10.1186/2193-1801-2-479",
language = "English",
volume = "2",
journal = "SpringerPlus",
issn = "2193-1801",
publisher = "Springer",
number = "Sep 22",

}